qa_id stringlengths 27 27 | qa_group_id stringlengths 28 32 | qa_family stringclasses 3
values | subtask_type stringclasses 7
values | qa_subtype stringclasses 3
values | cluster_id stringclasses 42
values | language stringclasses 1
value | split stringclasses 1
value | question stringlengths 148 1.41k | answer stringlengths 718 10.8k | claim_ids listlengths 0 8 | paper_ids listlengths 1 5 | evidence_span_ids listlengths 0 7 | association_ids listlengths 0 4 | hypothesis_ids listlengths 0 4 | record_json stringlengths 4.37k 33.7k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
QA:f5b4438c0c6aa8a424af7ce7 | QAG:1d693390c56a07af0c7bdac9 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "A comprehensive miRNA screening using The Cancer Genome Atlas (TCGA) dataset ( n = 260) combined with eight different miRNA target prediction programs led to the identification of a tumor suppressive miRNA, miR-148a-3p, as a potential negative regulator of PD-L1 expres... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:fc55ef74b445f6161e0b5be5","quotes":["A comprehensive miRNA screening using The Cancer Genome Atlas (TCGA) dataset... | [
"CLM:fc55ef74b445f6161e0b5be5",
"CLM:439debb91a7c2319411d2844"
] | [
"PMID:30872332"
] | [
"SPAN:cf9a46abbaec6c7ccdbf9c4a"
] | [] | [] | {"qa_id":"QA:f5b4438c0c6aa8a424af7ce7","qa_group_id":"QAG:1d693390c56a07af0c7bdac9","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"A comprehensive miRNA screening using The Cancer Genome Atlas (TCG... |
QA:f62564c3519e23a7ec4be26d | QAG:d68e1d9cb65a79f93a330f02 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Similar findings have also been observed in the CheckMate-142 study, in which nivolumab was given to patients with previously treated dMMR/MSI-H CRC, and those with PD-L1 ≥1% achieved an ORR of 29%, while those with PD-L1 <1% achieved an ORR of 28%"? Return the origina... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:572fe8772d149aaaee35e012","quotes":["Similar findings have also been observed in the Che... | [
"CLM:572fe8772d149aaaee35e012",
"CLM:439debb91a7c2319411d2844",
"CLM:eba667832912dfd0e18bf356"
] | [
"PMCID:PMC10772321",
"PMCID:PMC9496787"
] | [
"SPAN:6324fc4eaeb9fc95a4fb3c86",
"SPAN:69049fb9150b33478404d849"
] | [
"ASC2:5b234a2f8ad271adc2a05bc8"
] | [
"HYP:DCH:2a593ffdb8dafe0b3baa9ba6"
] | {"qa_id":"QA:f62564c3519e23a7ec4be26d","qa_group_id":"QAG:d68e1d9cb65a79f93a330f02","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Similar findings have also been observed in the CheckMate-142 stud... |
QA:f7a5460f36e00bde5665fccd | QAG:f1d20c57363f3651ccd485d5 | provenance_qa | paper_evidence_availability | provenance_qa | G007 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:35777274? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable an... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMID:35777274","verdict":"no_released_traceable_claim","reason":"No Cla... | [] | [
"PMID:35777274"
] | [] | [] | [] | {"qa_id":"QA:f7a5460f36e00bde5665fccd","qa_group_id":"QAG:f1d20c57363f3651ccd485d5","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G007","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:35777274? E... |
QA:f8830a7dfa16fbdd117f3fe5 | QAG:dde1dd9f3e9c9626ebfb3007 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Specifically, the ORR among patients with metastatic CRC, the most common cancer type in our cohort achieved 56.3%"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage wi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:718ec6a02159b35a10f9aec4","quotes":["Specifically, the ORR among patients with metastatic CRC, the most common ca... | [
"CLM:718ec6a02159b35a10f9aec4",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC10772321"
] | [
"SPAN:6812e365072ed2353438b208"
] | [] | [] | {"qa_id":"QA:f8830a7dfa16fbdd117f3fe5","qa_group_id":"QAG:dde1dd9f3e9c9626ebfb3007","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Specifically, the ORR among patients with metastatic CRC, the most... |
QA:f8a7ce890a358a18c512dcd3 | QAG:e5b43fd26f270d88428c6c88 | provenance_qa | paper_evidence_availability | provenance_qa | G007 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8295201? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC8295201","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC8295201"
] | [] | [] | [] | {"qa_id":"QA:f8a7ce890a358a18c512dcd3","qa_group_id":"QAG:e5b43fd26f270d88428c6c88","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G007","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8295201... |
QA:f8c148562b54dbf7ffd09766 | QAG:bc030010419b8c44b4d87c84 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Patients received the conventional ICI doses: intravenous pembrolizumab 200 mg every 3 weeks, avelumab 10 mg/kg intravenously every 2 weeks, and durvalumab 1,500 mg (20 mg/kg for patients with body weight ≤ 30 kg) intravenously every 4 weeks as described in each of the... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:5c6302925273f870dced07e0","quotes":["Patients were treated with the conventional ICI doses: intravenous pembroliz... | [
"CLM:5c6302925273f870dced07e0",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC9582482"
] | [
"SPAN:0cd72c237f61acad933d50db",
"SPAN:25dbf4a61b0680baf4713d35"
] | [] | [] | {"qa_id":"QA:f8c148562b54dbf7ffd09766","qa_group_id":"QAG:bc030010419b8c44b4d87c84","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Patients received the conventional ICI doses: intravenous pembroli... |
QA:f8df35de487d9724fabb759d | QAG:34c0cc1f459aff22ed962968 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Conclusions Pembrolizumab led to significantly longer progression-free survival than chemotherapy when received as first-line therapy for MSI-H-dMMR metastatic colorectal cancer, with fewer treatment-related adverse events"? Return the original wording with paper, Clai... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:386ab29d17844ecb442f252a","quotes":["Conclusions Pembrolizumab led to significantly longer progression-free survi... | [
"CLM:386ab29d17844ecb442f252a",
"CLM:439debb91a7c2319411d2844"
] | [
"PMID:33264544"
] | [
"SPAN:6a169608d4dbe93a334ae32b"
] | [] | [] | {"qa_id":"QA:f8df35de487d9724fabb759d","qa_group_id":"QAG:34c0cc1f459aff22ed962968","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Conclusions Pembrolizumab led to significantly longer progression-... |
QA:f8e601e31c123a8d9b866bf8 | QAG:2d830a6b88bc9db4bf69206f | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Our review aims to evaluate clinical trials that met the following criteria: a) patients with MSI/dMMR metastatic CRC; b) phase-II or phase-III; c) chemoimmunotherapy given in single-arm phase-II trials or as the experimental arm in phase-III trials; d) determination o... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:7640af3b016698b5ea0564e3","quotes":["Our review was designed to evaluate clinical trials that met the following c... | [
"CLM:7640af3b016698b5ea0564e3",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC8710086"
] | [
"SPAN:081d99d242be248abddfc4d2"
] | [] | [] | {"qa_id":"QA:f8e601e31c123a8d9b866bf8","qa_group_id":"QAG:2d830a6b88bc9db4bf69206f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Our review aims to evaluate clinical trials that met the following... |
QA:f9f38a040773028ffb508b1c | QAG:61fac27658cb87b49f301798 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "In consistent with previous finding, the expression of ZG16 is decreased in patients with MSI-H CRC and MLH1 silencing CRC ( Fig. 1 A)"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact s... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:7ab570fc288b5feb80756222","quotes":["In consistent with previous finding, the expression of ZG16 is significantly... | [
"CLM:7ab570fc288b5feb80756222",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC7773682"
] | [
"SPAN:9c3dba5a7415bdf01c1fffa9"
] | [] | [] | {"qa_id":"QA:f9f38a040773028ffb508b1c","qa_group_id":"QAG:61fac27658cb87b49f301798","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"In consistent with previous finding, the expression of ZG16 is dec... |
QA:fae3f37d98c7462c49512eb2 | QAG:04bd4b75f275d7a4482328e0 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Metastatic colorectal cancer often presents microsatellite instability which was associated with a positive response to immune therapy"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact s... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:a0d9e7b92f763b431029a99a","quotes":["Metastatic colorectal cancer often presents microsatellite instability which... | [
"CLM:a0d9e7b92f763b431029a99a",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC9818394"
] | [
"SPAN:1603e6a8d08d354a9df537f3"
] | [] | [] | {"qa_id":"QA:fae3f37d98c7462c49512eb2","qa_group_id":"QAG:04bd4b75f275d7a4482328e0","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Metastatic colorectal cancer often presents microsatellite instabi... |
QA:fcda12c6417ec4bbd09e5ca3 | QAG:953afbe09e7950c4b29ab16f | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "In bivariate analysis, elevated expression of cGAS and STING was associated with MSI-H colon cancer (Fisher’s exact test, both p = 0.0203)"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exa... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:4415a3f98e33b1b13b5b6071","quotes":["In bivariate analysis, elevated expression of cGAS and STING was positively ... | [
"CLM:4415a3f98e33b1b13b5b6071",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC9818394"
] | [
"SPAN:8bf11ed90655696b26f8bf8e"
] | [] | [] | {"qa_id":"QA:fcda12c6417ec4bbd09e5ca3","qa_group_id":"QAG:953afbe09e7950c4b29ab16f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"In bivariate analysis, elevated expression of cGAS and STING was a... |
QA:0007d189c0ef0a10d07960aa | QAG:6a7f43234fa6a36e59cf1de2 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage locates the statement "Circulating tumor DNA analysis detects minimal residual disease and predicted recurrence in patients with stage II colon cancer"? If it is only a reference-list entry, explicitly abstain from treating it as sufficient full-text evidence.
Integrated provenance requireme... | {"answer_type":"integrated_provenance","embedded_answer_types":["limited_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":{"answer_type":"limited_evidence_retrieval","claim_id":"CLM:9ebbde126c7621674d69d567","quotes":["Circulating tumor DNA analysis detects... | [
"CLM:9ebbde126c7621674d69d567",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC9648419"
] | [
"SPAN:022ac90de79847e3992503a9"
] | [] | [] | {"qa_id":"QA:0007d189c0ef0a10d07960aa","qa_group_id":"QAG:6a7f43234fa6a36e59cf1de2","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage locates the statement \"Circulating tumor DNA analysis detects minimal residual disease and... |
QA:001cb673b1344e746a80232d | QAG:081f274c8124c4fc17272f0c | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "We also found improved DFS for right-sided early-stage CRC when compared with left-sided disease, both in stage II and III disease"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact suppo... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c5e9c02030499cb56f75b50e","quotes":["We also found improved DFS for right-sided early-stage CRC when compared wit... | [
"CLM:c5e9c02030499cb56f75b50e",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC6857614"
] | [
"SPAN:46a079b402d8384c76269073"
] | [] | [] | {"qa_id":"QA:001cb673b1344e746a80232d","qa_group_id":"QAG:081f274c8124c4fc17272f0c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"We also found improved DFS for right-sided early-stage CRC when co... |
QA:0075cc7b71e7652ef9723541 | QAG:3127bf486d54bf69c5cbe40d | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Next, to validate the function of epigenetic-related gene mutations further in predicting responsiveness to ICI therapy in MSS-CRC, we collected a clinical cohort of 89 MSS-CRC patients who had received PD-1 mAb-based treatment"? Return the original wording with paper,... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ec3392259a18281985fc047e","quotes":["Next, to validate the function of epigenetic-relate... | [
"CLM:ec3392259a18281985fc047e",
"CLM:76b5c39658e904fe9e6f7dd7",
"CLM:fb6a0c9817f49af49dcab0f4"
] | [
"PMCID:PMC9720302",
"PMCID:PMC6538740"
] | [
"SPAN:cf91727b11a68ae6f094bce2",
"SPAN:61b095271cf01ea457cdfcab"
] | [
"ASC2:d39f987f783d02d29b0790b2"
] | [
"HYP:DCH:024bac6d96855edf67ccdc9e"
] | {"qa_id":"QA:0075cc7b71e7652ef9723541","qa_group_id":"QAG:3127bf486d54bf69c5cbe40d","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Next, to validate the function of epigenetic-related gene mutation... |
QA:0403c90e8d1b6850f8b4361c | QAG:a8b58b6fa6552c97b2295950 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Although our results confirm the notion that activated immune cytotoxicity represents a potent determinant of the risk of distant dissemination, it is also known that immune and stromal infiltration patterns can be predicted by assessing intrinsic tumor cell epithelial... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:e8b3fa82593396401c14499a","quotes":["Although our results confirm the notion that activated immune cytotoxicity r... | [
"CLM:e8b3fa82593396401c14499a",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC6857614"
] | [
"SPAN:4d9923cf046a6f75641d9a70"
] | [] | [] | {"qa_id":"QA:0403c90e8d1b6850f8b4361c","qa_group_id":"QAG:a8b58b6fa6552c97b2295950","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Although our results confirm the notion that activated immune cyto... |
QA:087b5241f15afe8dcaeff052 | QAG:a4a96ecd58d0787ee8494c5c | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Our risk score was associated with tumor-infiltrated immune cells of MSS-EO-CRC and had a reliable prediction on the prognosis of patients"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exa... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:04216420b94a56bc6cde6283","quotes":["Our risk score was associated with tumor-infiltrated immune cells of MSS-EO-... | [
"CLM:04216420b94a56bc6cde6283",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10314951"
] | [
"SPAN:f990fdb1399700893983a29a"
] | [] | [] | {"qa_id":"QA:087b5241f15afe8dcaeff052","qa_group_id":"QAG:a4a96ecd58d0787ee8494c5c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Our risk score was associated with tumor-infiltrated immune cells ... |
QA:096b781af8b9b0f473628348 | QAG:f0aeb228250962df1a233d30 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "This mutation frequency was higher than that of any previous marker in the population, such as POLE or DDR mutations, and was closer to the potential benefit ratio in MSS-CRC clinical trials"? Return the original wording with paper, Claim, and Evidence Span references.... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:4877189f8ed9a5af79a681c4","quotes":["This mutation frequency was higher than that of any previous marker in the p... | [
"CLM:4877189f8ed9a5af79a681c4",
"CLM:76b5c39658e904fe9e6f7dd7"
] | [
"PMCID:PMC9720302"
] | [
"SPAN:086e932faeb691b4b354833e"
] | [] | [] | {"qa_id":"QA:096b781af8b9b0f473628348","qa_group_id":"QAG:f0aeb228250962df1a233d30","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"This mutation frequency was higher than that of any previous marke... |
QA:09e78f9103ceafcb62b63a5b | QAG:9e98bdae127e8e7c4863e4e1 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "To evaluate whether ATG16L1 expression was associated with response to ICI in non-MSI CRC, we evaluated tumor gene expression data from IMblaze370 (NCT02788279), a large ( n = 363) multi-center phase III trial in locally advanced or metastatic CRC where disease progres... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:1e565da98de1c0e494ba3bf3","quotes":["To evaluate whether ATG16L1 expression is associated with response to ICI in... | [
"CLM:1e565da98de1c0e494ba3bf3",
"CLM:76b5c39658e904fe9e6f7dd7"
] | [
"PMCID:PMC10517947"
] | [
"SPAN:701e3605e87a4db0dc329201"
] | [] | [] | {"qa_id":"QA:09e78f9103ceafcb62b63a5b","qa_group_id":"QAG:9e98bdae127e8e7c4863e4e1","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"To evaluate whether ATG16L1 expression was associated with respons... |
QA:0aaadd90393a69afd393226e | QAG:97ba46dccfdaa3f0bce2f44d | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Single-cell gene expression analysis of human CRC tumors (GSE146771) 38 confirmed increased ATG16L1 transcript levels in the tumor epithelium when compared to other cellular compartments of the CRC tumor microenvironment (Fig. 1d , expression of lineage markers associa... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:1d0dcf0c071a086363404b97","quotes":["Single-cell gene expression analysis of human CRC tumors (GSE146771) 38 conf... | [
"CLM:1d0dcf0c071a086363404b97",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10517947"
] | [
"SPAN:05dbda9ddb644b5b4daf856b"
] | [] | [] | {"qa_id":"QA:0aaadd90393a69afd393226e","qa_group_id":"QAG:97ba46dccfdaa3f0bce2f44d","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Single-cell gene expression analysis of human CRC tumors (GSE14677... |
QA:0d0f1cfe9cda88fe4562fe4e | QAG:291b5dbc69b35855c683bd40 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "We observed that the expression levels of genes related to MSI-H CRC-activated immune cells (such as B cells, CD4 + T cells, CD8 + T cells, macrophages, neutrophils, and NK cells) were increased ( Figures 3A,B )"? Return the original wording with paper, Claim, and Evid... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:58dad0f857ad8429b5b20985","quotes":["We observed that the expression levels of genes related to MSI-H CRC-activat... | [
"CLM:58dad0f857ad8429b5b20985",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC7435056"
] | [
"SPAN:bc292e016a3fa65757d5efe4"
] | [] | [] | {"qa_id":"QA:0d0f1cfe9cda88fe4562fe4e","qa_group_id":"QAG:291b5dbc69b35855c683bd40","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"We observed that the expression levels of genes related to MSI-H C... |
QA:0debab1259327b61682172ff | QAG:af72d58662aa39b49556e04b | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Deletion of Atg16l1 in engineered murine colon cancer organoids inhibits tumor growth in primary (colon) and metastatic (liver and lung) niches in syngeneic female hosts, primarily due to increased sensitivity to IFN-γ-mediated immune pressure"? Return the original wor... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:a2362a985b2319b123043b4d","quotes":["Deletion of Atg16l1 in engineered murine colon cancer organoids inhibits tum... | [
"CLM:a2362a985b2319b123043b4d",
"CLM:76b5c39658e904fe9e6f7dd7"
] | [
"PMCID:PMC10517947"
] | [
"SPAN:0818f40ff09ea842135bbe32"
] | [] | [] | {"qa_id":"QA:0debab1259327b61682172ff","qa_group_id":"QAG:af72d58662aa39b49556e04b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Deletion of Atg16l1 in engineered murine colon cancer organoids in... |
QA:0f181bd2c27abb5eaae909aa | QAG:9bfe2aa0c172e0c348f501cf | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Recently, investigations 36 in gastric cancer patients demonstrated that positive PD-L1 status in tumor cells (tPD-L1) was associated with a higher density of CD8 + TILs"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenan... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:76b5c39658e904fe9e6f7dd7","quotes":["Recently, investigations 36 in gastric cancer patients demonstrated that pos... | [
"CLM:76b5c39658e904fe9e6f7dd7",
"CLM:0073c2120ee0a21e8a57f5ce"
] | [
"PMCID:PMC8114827"
] | [
"SPAN:c7930208b7f471b55a12d1b3"
] | [] | [] | {"qa_id":"QA:0f181bd2c27abb5eaae909aa","qa_group_id":"QAG:9bfe2aa0c172e0c348f501cf","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Recently, investigations 36 in gastric cancer patients demonstrate... |
QA:0f2335c9968a4a5172343f83 | QAG:5a68c475442ce166c1f9fa2a | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Mouse PMs ( C ) and human colorectal cancer TAMs ( D ) received various concentrations of C-6-S. Flow cytometry detected the CD11c − CD206 + or CD86 − CD163 + M2 macrophages"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated prov... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:dae2dbbcb4177d74c84d908f","quotes":["Mouse PMs ( C ) and human colorectal cancer TAMs ( D ) were treated with var... | [
"CLM:dae2dbbcb4177d74c84d908f",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC9414301"
] | [
"SPAN:af16837e4896e958ecaeb040"
] | [] | [] | {"qa_id":"QA:0f2335c9968a4a5172343f83","qa_group_id":"QAG:5a68c475442ce166c1f9fa2a","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Mouse PMs ( C ) and human colorectal cancer TAMs ( D ) received va... |
QA:14150b80c848fe084099816a | QAG:dd48261b04640c1da7bd0470 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "This raises the possibility that drugs targeting STAT1 might improve IFNγ promoted PD-L1 expression and enhance the efficiency of anti-PD-1 immunotherapy"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements:... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:cfbac14dbddd79d1791da61f","quotes":["This raises the possibility that drugs targeting STAT1 might improve IFNγ-in... | [
"CLM:cfbac14dbddd79d1791da61f",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC8114827"
] | [
"SPAN:9a44d221c95d33663be52381",
"SPAN:d3b187481abf92b610366765"
] | [] | [] | {"qa_id":"QA:14150b80c848fe084099816a","qa_group_id":"QAG:dd48261b04640c1da7bd0470","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"This raises the possibility that drugs targeting STAT1 might impro... |
QA:14d4670325d7d1e368ed4fbe | QAG:1aba690aaebb261c5038d0e1 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Since only CRC patients with MSS were included in our study, most of these subjects are refractory to immune monotherapy, mainly caused by the low levels of tumor-infiltrating lymphocytes and tumor mutation burden 20 , 21"? Return the original wording with paper, Claim... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:5d4009e6c75388d444b14d3f","quotes":["Since only CRC patients with MSS were included in our study, most of these s... | [
"CLM:5d4009e6c75388d444b14d3f",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10314951"
] | [
"SPAN:b919374fed6e2838c9c7adbb"
] | [] | [] | {"qa_id":"QA:14d4670325d7d1e368ed4fbe","qa_group_id":"QAG:1aba690aaebb261c5038d0e1","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Since only CRC patients with MSS were included in our study, most ... |
QA:16c20e6e3401085914911d9a | QAG:7593afafbd3433a4bcc1e893 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Specifically, relative to MSS disease, MSI-high CRC is characterized by increased infiltration by T-cells with both cytotoxic and Th1 phenotypes, but also expression of high levels of inhibitory immune surface markers such as PD-1, PD-L1, CLTA-4. 6 MEK inhibition (MEKi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c80d7cf069adbd1d6dd3a711","quotes":["Specifically, relative to ... | [
"CLM:c80d7cf069adbd1d6dd3a711",
"CLM:64822c34f03e6ab9a02ee6f5",
"CLM:28ab17ada0f4f50211ffb2cd",
"CLM:2560bc1f8e2c9438c608e023"
] | [
"PMCID:PMC9422817",
"PMCID:PMC10151977",
"PMCID:PMC7212380"
] | [
"SPAN:dd72ac8826e8f7541d5cee99",
"SPAN:28060c64c1a704e1bf44cd69",
"SPAN:52019a971ff49ae810a0a044",
"SPAN:6dc39dfa43d2ca1c1df4235b"
] | [
"ASC2:8b9d6efa5555febc2086e5d2",
"ASC2:2447979a2c942eb69c534903"
] | [
"HYP:DCH:a7ad4e3987614802ef4712aa",
"HYP:DCH:e35fbef2d9f94dc5d70b8f9e"
] | {"qa_id":"QA:16c20e6e3401085914911d9a","qa_group_id":"QAG:7593afafbd3433a4bcc1e893","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Specifically, relative to MSS disease, MSI-high CRC is characteriz... |
QA:18c4816fcbe0be4e5fbbdd58 | QAG:62a953effab40040befd5733 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "This analysis highlighted that GQD has 79 significant targets in CRC and inhibits CRC by regulating the cell cycle, focal adhesion and NOD-like receptor signalling pathway, which are promoted by CRC-related oncogenes and dysregulated suppressor genes"? Return the origi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:76523befd070055ba4ff0934","quotes":["This analysis highlighted that GQD has 79 significant targets in CRC and inh... | [
"CLM:76523befd070055ba4ff0934",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC6538740"
] | [
"SPAN:14437a5976297657164537d1"
] | [] | [] | {"qa_id":"QA:18c4816fcbe0be4e5fbbdd58","qa_group_id":"QAG:62a953effab40040befd5733","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"This analysis highlighted that GQD has 79 significant targets in C... |
QA:19f32387aabcbcf25929bed0 | QAG:34f9f3346f8863e360e3816c | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "From December 2019 to August 2022, we assessed the outcomes of MSS patients with refractory advanced CRC who received fruquintinib in combination with toripalimab at the First Hospital of Lanzhou University"? Return the original wording with paper, Claim, and Evidence ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:e9329c586b65f7f7ca64c225","quotes":["From December 2019 to August 2022, we assessed the outcomes of MSS patients ... | [
"CLM:e9329c586b65f7f7ca64c225",
"CLM:76b5c39658e904fe9e6f7dd7"
] | [
"PMCID:PMC10186513"
] | [
"SPAN:dff37a1be3dfe75db8c3704c"
] | [] | [] | {"qa_id":"QA:19f32387aabcbcf25929bed0","qa_group_id":"QAG:34f9f3346f8863e360e3816c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"From December 2019 to August 2022, we assessed the outcomes of MSS... |
QA:1a7d44ac9af3c4fbe683f574 | QAG:59c5f6800fe9557410127743 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "However, a combination of TNF and IFNγ promoted death of CRC organoids"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and Evidence Span reference... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:853f88a274b80b3adcb4c88a","quotes":["However, a combination of TNF and IFNγ induced death of CRC organoids."],"ci... | [
"CLM:853f88a274b80b3adcb4c88a",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10517947"
] | [
"SPAN:b869a2d1d70db6a9d6d86c46"
] | [] | [] | {"qa_id":"QA:1a7d44ac9af3c4fbe683f574","qa_group_id":"QAG:59c5f6800fe9557410127743","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"However, a combination of TNF and IFNγ promoted death of CRC organ... |
QA:1cce0ab7b54cb45b1f5c6507 | QAG:69b8bf8b2952a39266f932f1 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Methods We conducted a single-center retrospective study by collecting relevant data on patients with MSS/pMMR advanced CRC who received fruquintinib coupled with PD-1 inhibitors in the First Affiliated Hospital of Zhengzhou University between August 2019 and November ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:22c7b7919832fb99c8ebd90c","quotes":["Methods We conducted a sin... | [
"CLM:22c7b7919832fb99c8ebd90c",
"CLM:64822c34f03e6ab9a02ee6f5",
"CLM:d1eccd4fb86bfca3e5ec813f",
"CLM:fb6a0c9817f49af49dcab0f4"
] | [
"PMCID:PMC9472213",
"PMCID:PMC9414301",
"PMCID:PMC6538740"
] | [
"SPAN:5a1e753cf8e56545027355e2",
"SPAN:b18c85a9dd0d05a0b163fe6a",
"SPAN:61b095271cf01ea457cdfcab"
] | [
"ASC2:01b6e76af7d49c6e1a0943c2",
"ASC2:3587d1e0ae09244af1b2c624"
] | [
"HYP:DCH:054cb2133f13c935b2f88fa5"
] | {"qa_id":"QA:1cce0ab7b54cb45b1f5c6507","qa_group_id":"QAG:69b8bf8b2952a39266f932f1","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Methods We conducted a single-center retrospective study by collec... |
QA:1e343897e382094ff3f87729 | QAG:aba906f7c4750bccd5dbb537 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "In our study, the better efficacy of PD-1 antibody in the treatment of MSS-type CRC was associated with the glycerophospholipid metabolic pathway, while the metabolomics metabolite pathway enrichment was enriched in the glycerophospholipid metabolic pathway, accompanie... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ae130298a1757b7ee402997a","quotes":["In our study, the better efficacy of PD-1 antibody ... | [
"CLM:ae130298a1757b7ee402997a",
"CLM:76b5c39658e904fe9e6f7dd7",
"CLM:187792abec08d7cee4862b6a",
"CLM:d1eccd4fb86bfca3e5ec813f"
] | [
"PMCID:PMC7212380",
"PMCID:PMC9472213",
"PMCID:PMC9414301"
] | [
"SPAN:13cf1ac66618d7b7cb327650",
"SPAN:c469af1f48069fbc99c3bd50",
"SPAN:b18c85a9dd0d05a0b163fe6a"
] | [
"ASC2:2d400c71b0e1fb12392e554d",
"ASC2:8ef9885551b90774662e7df1"
] | [
"HYP:DCH:8c3664fee95b199e8d4f2e17"
] | {"qa_id":"QA:1e343897e382094ff3f87729","qa_group_id":"QAG:aba906f7c4750bccd5dbb537","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"In our study, the better efficacy of PD-1 antibody in the treatmen... |
QA:1f8cf53b0f86a22c363e7841 | QAG:3d8fec453344cac1c3f71bc6 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "These results are in line with our data showing a stronger signal for improved outcomes with CytoLym high scores mainly in the MSS population"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:8ac93b7d2e355c5feee4dfe8","quotes":["These results are in line with our data showing a stronger signal for improv... | [
"CLM:8ac93b7d2e355c5feee4dfe8",
"CLM:76b5c39658e904fe9e6f7dd7"
] | [
"PMCID:PMC6857614"
] | [
"SPAN:b19249d3302cec0a09441a62",
"SPAN:d50c170fbb41e3005d2a7443"
] | [] | [] | {"qa_id":"QA:1f8cf53b0f86a22c363e7841","qa_group_id":"QAG:3d8fec453344cac1c3f71bc6","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"These results are in line with our data showing a stronger signal ... |
QA:247018dc64df5cf5a18af0fa | QAG:32e520146abca4a834e2f733 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "However, in the TCGA-CRC cohort, compared with the MSS/MSI-L + tumor mutational burden-high (TMB-H) group, the MSI-H group experienced prolonged OS ( P = 0.015; Figure 1D )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated prove... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:5ae618f2341a419c3ef1b392","quotes":["However, in the TCGA-CRC cohort, compared with the MSS/MSI-L + tumor mutatio... | [
"CLM:5ae618f2341a419c3ef1b392",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC7435056"
] | [
"SPAN:28a5c2ca25688f62bdf85beb"
] | [] | [] | {"qa_id":"QA:247018dc64df5cf5a18af0fa","qa_group_id":"QAG:32e520146abca4a834e2f733","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"However, in the TCGA-CRC cohort, compared with the MSS/MSI-L + tum... |
QA:253d6693d55e650fcf678041 | QAG:f219b5e5a8397bdf0f1715f9 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "While not fully characterized in colorectal cancer, inhibition of TGFβ3 in preclinical models of glioblastoma multiforme was associated with decreased expression of downstream SMAD oncogenes, decreased tumor invasiveness, and dampened TGFβ1/TGFβ2 signaling"? Return the... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:fb32e2e7ed0885384f1749a8","quotes":["While not fully characterized in colorectal cancer, inhibition of TGFβ3 in p... | [
"CLM:fb32e2e7ed0885384f1749a8",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC9648419"
] | [
"SPAN:43f2a9fbefb9dcff01fdbd01"
] | [] | [] | {"qa_id":"QA:253d6693d55e650fcf678041","qa_group_id":"QAG:f219b5e5a8397bdf0f1715f9","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"While not fully characterized in colorectal cancer, inhibition of ... |
QA:298c865a91e7d1b5b20c2af6 | QAG:ba12f69aa8b68fa1687fabbf | provenance_qa | paper_evidence_availability | provenance_qa | G008 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC7446507? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC7446507","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC7446507"
] | [] | [] | [] | {"qa_id":"QA:298c865a91e7d1b5b20c2af6","qa_group_id":"QAG:ba12f69aa8b68fa1687fabbf","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G008","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC7446507... |
QA:2a8c8fc1775480d2236e9676 | QAG:cd6b9ba568025aa68483de3a | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "5 Radiotherapy effectively induces the secretion of type I IFN within the tumor microenvironments to generate anti-tumor immunity by activating and recruiting CD8 + T cell infiltration, 6 which was associated with a favorable prognosis in CRC 7 and are more responsive ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:0ced1357dd662bb78bc5c2da","quotes":["5 Radiotherapy effectively induces the secretion of type I IFN within the tu... | [
"CLM:0ced1357dd662bb78bc5c2da",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10813565"
] | [
"SPAN:f40eaa72bf058e2b9fc2df8d"
] | [] | [] | {"qa_id":"QA:2a8c8fc1775480d2236e9676","qa_group_id":"QAG:cd6b9ba568025aa68483de3a","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"5 Radiotherapy effectively induces the secretion of type I IFN wit... |
QA:2aab766bc49ad79d2cb60834 | QAG:5721476ba085fe018f71d015 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "PD-L1 expression in colorectal cancer was associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:3cc797726363fb29928626a6","quotes":["43. Rosenbaum MW, Bledsoe ... | [
"CLM:3cc797726363fb29928626a6",
"CLM:64822c34f03e6ab9a02ee6f5",
"CLM:b2d474f7680804de4fef4716",
"CLM:28ab17ada0f4f50211ffb2cd"
] | [
"PMCID:PMC5823560",
"PMCID:PMC8114827",
"PMCID:PMC10151977"
] | [
"SPAN:bf31c33b34baabc97df027de",
"SPAN:242f3d146fd0461b1fda0288",
"SPAN:28060c64c1a704e1bf44cd69",
"SPAN:52019a971ff49ae810a0a044"
] | [
"ASC2:2a028abb8b5927a8b08d5b46",
"ASC2:b8eb3922d82ab279770034f9"
] | [
"HYP:DCH:557c6ffd3fccb9eb86f0a171",
"HYP:DCH:23ba703a3e15c9004e717e23"
] | {"qa_id":"QA:2aab766bc49ad79d2cb60834","qa_group_id":"QAG:5721476ba085fe018f71d015","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"PD-L1 expression in colorectal cancer was associated with microsat... |
QA:2b560afe747f97dab089a944 | QAG:3ce19dedda5f724fdfc74dfa | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Reduced hGC-1 protein expression was associated with malignant progression of colon carcinoma"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c428a1673e90fdefc7760a4b","quotes":["Reduced hGC-1 protein expression is associated with malignant progression of... | [
"CLM:c428a1673e90fdefc7760a4b",
"CLM:76b5c39658e904fe9e6f7dd7"
] | [
"PMCID:PMC10129169"
] | [
"SPAN:64454872e14fc73af2346a87"
] | [] | [] | {"qa_id":"QA:2b560afe747f97dab089a944","qa_group_id":"QAG:3ce19dedda5f724fdfc74dfa","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Reduced hGC-1 protein expression was associated with malignant pro... |
QA:2cb13963963c5eae849a67e3 | QAG:b4637829a05df8ac3962c774 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "However, only a small subset of CRC patients has thus far demonstrated responses to ICIs, specifically those exhibiting increased tumor mutation burden caused by defective mismatch repair machinery (dMMR; also termed microsatellite instability, MSI) 2 – 4"? Return the ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ad2502290fdbd8ebd0657e04","quotes":["However, only a small subset of CRC patients has thus far demonstrated respo... | [
"CLM:ad2502290fdbd8ebd0657e04",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10517947"
] | [
"SPAN:2e43ee14c5f354fdeb5817c2"
] | [] | [] | {"qa_id":"QA:2cb13963963c5eae849a67e3","qa_group_id":"QAG:b4637829a05df8ac3962c774","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"However, only a small subset of CRC patients has thus far demonstr... |
QA:2e6d32f5f0c9c6afaf7052fe | QAG:918a4adb8787664bd73fc699 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Importantly, tolinapant promoted apoptosis was augmented by FOLFOX in human colorectal cancer and murine organoid models in vitro and in vivo , due (at least in part) to FOLFOX-induced downregulation of class I histone deacetylases (HDAC), leading to acetylation of the... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ee1092c630beeb14910bb16b","quotes":["In cells co-cultured with TNFα to mimic an inflammatory tumor microenvironme... | [
"CLM:ee1092c630beeb14910bb16b",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC7611622"
] | [
"SPAN:b8f746d9a3fd6c9da1312352"
] | [] | [] | {"qa_id":"QA:2e6d32f5f0c9c6afaf7052fe","qa_group_id":"QAG:918a4adb8787664bd73fc699","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Importantly, tolinapant promoted apoptosis was augmented by FOLFOX... |
QA:308053cd1de070091a31a023 | QAG:170a0df24e3cc8335d23a87d | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "It is believed that this was associated with the rich lymphocyte infiltration which would give a robust immune response against the tumor"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exac... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9f42352f1afa77d634d9279d","quotes":["It is believed that this is associated with the rich lymphocyte infiltration... | [
"CLM:9f42352f1afa77d634d9279d",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC5823560"
] | [
"SPAN:e2b7be6c292f1571bd8f1e78",
"SPAN:e400b420bfce64896e30fdea"
] | [] | [] | {"qa_id":"QA:308053cd1de070091a31a023","qa_group_id":"QAG:170a0df24e3cc8335d23a87d","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"It is believed that this was associated with the rich lymphocyte i... |
QA:30bf50ceca911dfd909e0d21 | QAG:87d08c5343e582ce0676151f | provenance_qa | paper_evidence_availability | provenance_qa | G008 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8430485? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC8430485","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC8430485"
] | [] | [] | [] | {"qa_id":"QA:30bf50ceca911dfd909e0d21","qa_group_id":"QAG:87d08c5343e582ce0676151f","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G008","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8430485... |
QA:31abdfdf833dbe88aa49da86 | QAG:16927ab72877940b52e427e8 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "According to the REGOTORI study from China, patients with resistant MSS CRC who received the combination of regorafenib and toripalimab had an OS of 15.5 months, indicating that the antitumor activity of this regimen was long-lasting, and the ORR was up to 30% in the p... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:3015cde80519f486979f1ada","quotes":["According to the REGOTORI study from China, patient... | [
"CLM:3015cde80519f486979f1ada",
"CLM:64822c34f03e6ab9a02ee6f5",
"CLM:e638238421b377ca7c30cbf2"
] | [
"PMCID:PMC10186513",
"PMCID:PMC9720302"
] | [
"SPAN:4fbee75754e85c40a8b62900",
"SPAN:e99f8d1515afb4e422a6570b"
] | [
"ASC2:fa37904201094ded3b4b3eaf"
] | [] | {"qa_id":"QA:31abdfdf833dbe88aa49da86","qa_group_id":"QAG:16927ab72877940b52e427e8","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"According to the REGOTORI study from China, patients with resistan... |
QA:32dd6bfaa72c6930b8cadd2b | QAG:44bc6ed154d7bd9413e074dc | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Gene expression analysis of patient samples from The Cancer Genome Atlas (TCGA) also showed ATG16L1 transcript levels to be increased in human CRC compared to normal adjacent tissue (Supplementary Fig. 1a )"? Return the original wording with paper, Claim, and Evidence ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:8551346351542a861c99172d","quotes":["Gene expression analysis of patient samples from The Cancer Genome Atlas (TC... | [
"CLM:8551346351542a861c99172d",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10517947"
] | [
"SPAN:e409bb58f12c8031d0cc9f48"
] | [] | [] | {"qa_id":"QA:32dd6bfaa72c6930b8cadd2b","qa_group_id":"QAG:44bc6ed154d7bd9413e074dc","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Gene expression analysis of patient samples from The Cancer Genome... |
QA:3467c57fac621fa90609ab9b | QAG:4826f6fb7f294bde30a0a23b | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Importantly, tolinapant-induced apoptosis was augmented by FOLFOX in human colorectal cancer and murine organoid models in vitro and in vivo , due (at least in part) to FOLFOX promoted downregulation of class I histone deacetylases (HDAC), leading to acetylation of the... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:a816a9b23ba369743dfabee1","quotes":["In cells co-cultured with TNFα to mimic an inflammatory tumor microenvironme... | [
"CLM:a816a9b23ba369743dfabee1",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC7611622"
] | [
"SPAN:b8f746d9a3fd6c9da1312352"
] | [] | [] | {"qa_id":"QA:3467c57fac621fa90609ab9b","qa_group_id":"QAG:4826f6fb7f294bde30a0a23b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Importantly, tolinapant-induced apoptosis was augmented by FOLFOX ... |
QA:347c2548a40e9f44857f947a | QAG:ef649ec53a8f6c7e66f1ad18 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "However, in some cases, tumor PD-L1 expression cannot be promoted even in the presence of abundant T lymphocytes, in locally advanced colorectal cancer patients who receive preoperative neoadjuvant concurrent chemoradiotherapy (CCRT)"? Return the original wording with ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:48ad9319190409fc5c3f4297","quotes":["However, in some cases, tumor PD-L1 expression cannot be induced, even in th... | [
"CLM:48ad9319190409fc5c3f4297",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10813565"
] | [
"SPAN:fe96eaaf2382312eef1e50ac"
] | [] | [] | {"qa_id":"QA:347c2548a40e9f44857f947a","qa_group_id":"QAG:ef649ec53a8f6c7e66f1ad18","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"However, in some cases, tumor PD-L1 expression cannot be promoted ... |
QA:350f2a98b9759809dcd4e226 | QAG:c53585b390e6336caa95c541 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "The rationale for this combination was based on the hypothesis that the efficacy of immune-checkpoint inhibitors in MSS CRC may be increased by augmenting priming and T-cell activation in the TME"? Return the original wording with paper, Claim, and Evidence Span refere... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:823c7822b9bfa0515b99f972","quotes":["The rationale for this combination was based on the hypothesis that the effi... | [
"CLM:823c7822b9bfa0515b99f972",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC9422817"
] | [
"SPAN:03f23c4d3a9f7a8b0e40bbc7"
] | [] | [] | {"qa_id":"QA:350f2a98b9759809dcd4e226","qa_group_id":"QAG:c53585b390e6336caa95c541","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"The rationale for this combination was based on the hypothesis tha... |
QA:3541d557c96f13a65a732fc7 | QAG:049f72e4006b90e27538be35 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Figure 3 Epigenetic_Mut was associated with increased immune activity in MSS-CRC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and Evidence Span... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:37fa5dc708811faa392c2e51","quotes":["Figure 3 Epigenetic_Mut is associated with increased immune activity in MSS-... | [
"CLM:37fa5dc708811faa392c2e51",
"CLM:76b5c39658e904fe9e6f7dd7"
] | [
"PMCID:PMC9720302"
] | [
"SPAN:2c6a2dbfbbcf8c8f5f242bd0"
] | [] | [] | {"qa_id":"QA:3541d557c96f13a65a732fc7","qa_group_id":"QAG:049f72e4006b90e27538be35","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Figure 3 Epigenetic_Mut was associated with increased immune activ... |
QA:362a54ebe9e1b82faaa2866c | QAG:471be45bf90c9d733c899f06 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Univariate and multivariate analysis of PD-L1 promoter loci (cg15837913 and cg19724470) in locally advanced colorectal cancer who received preoperative CCRT 5-year DFS Parameters Univariate analysis Multivariate analysis HR 95% CI p value HR 95% CI p value pT stage (T3... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:44b4573342bf8550ffb50c63","quotes":["Table 2. Univariate and multivariate analysis of PD-L1 promoter loci (cg1583... | [
"CLM:44b4573342bf8550ffb50c63",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10813565"
] | [
"SPAN:b20fc422dd698ee6b2fdd223"
] | [] | [] | {"qa_id":"QA:362a54ebe9e1b82faaa2866c","qa_group_id":"QAG:471be45bf90c9d733c899f06","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Univariate and multivariate analysis of PD-L1 promoter loci (cg158... |
QA:36cb02b783ed2b9703ad5b26 | QAG:26a24bd86de5b95149febcdd | provenance_qa | paper_evidence_availability | provenance_qa | G008 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC7603874? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC7603874","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC7603874"
] | [] | [] | [] | {"qa_id":"QA:36cb02b783ed2b9703ad5b26","qa_group_id":"QAG:26a24bd86de5b95149febcdd","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G008","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC7603874... |
QA:37a14b49cf4c9393b20c6da2 | QAG:2ebc8a70848530a01e559418 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "To sum up, Surfen markedly increased anti–PD-1 response in MSS colorectal cancer"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and Evidence Span... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:d1eccd4fb86bfca3e5ec813f","quotes":["To sum up, Surfen markedly enhanced anti–PD-1 respo... | [
"CLM:d1eccd4fb86bfca3e5ec813f",
"CLM:64822c34f03e6ab9a02ee6f5",
"CLM:ae130298a1757b7ee402997a"
] | [
"PMCID:PMC9414301",
"PMCID:PMC7212380"
] | [
"SPAN:b18c85a9dd0d05a0b163fe6a",
"SPAN:13cf1ac66618d7b7cb327650"
] | [
"ASC2:8ef9885551b90774662e7df1"
] | [
"HYP:DCH:3ed66573acacfbdf480ea61e"
] | {"qa_id":"QA:37a14b49cf4c9393b20c6da2","qa_group_id":"QAG:2ebc8a70848530a01e559418","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"To sum up, Surfen markedly increased anti–PD-1 response in MSS col... |
QA:38619a644b626cba917b4442 | QAG:753483525abdbca6b52d1dd5 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "The KEYNOTE-016 study showed that 62% (7/13) of patients with MSI-H CRC pretreated with ICIs achieved an objective response and did not reach the median for progression-free survival (PFS) or overall survival (OS) ( 6 )"? Return the original wording with paper, Claim, ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:0e433fbe2b7a9427bf15375e","quotes":["The KEYNOTE-016 study showed that 62% (7/13) of patients with MSI-H CRC pret... | [
"CLM:0e433fbe2b7a9427bf15375e",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC7435056"
] | [
"SPAN:302072dc28b41f8d14761293"
] | [] | [] | {"qa_id":"QA:38619a644b626cba917b4442","qa_group_id":"QAG:753483525abdbca6b52d1dd5","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"The KEYNOTE-016 study showed that 62% (7/13) of patients with MSI-... |
QA:38fef554598234049d5828f7 | QAG:6e576a10b78b7a1e4721bc1a | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "We found that increased expression of cIAP1 and cIAP2 (but not XIAP) significantly correlated with poor prognosis in patients with microsatellite stable (MSS) stage III colorectal cancer treated with 5-fluorouracil (5FU)-based adjuvant chemotherapy, suggesting their in... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:3c06ef71b6ceacc707916458","quotes":["We found that elevated expression of cIAP1 and cIAP2 (but not XIAP) signific... | [
"CLM:3c06ef71b6ceacc707916458",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC7611622"
] | [
"SPAN:364ffa0d833f020d66babd64"
] | [] | [] | {"qa_id":"QA:38fef554598234049d5828f7","qa_group_id":"QAG:6e576a10b78b7a1e4721bc1a","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"We found that increased expression of cIAP1 and cIAP2 (but not XIA... |
QA:39e0e2eab615b100b0ae625e | QAG:e1c56ec9b0423c1b100e5969 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "In the ICI-treated CRC cohort, the MANTIS score was correlated with TMB ( P < 0.001; Figure 4A )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, a... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:6f536da86cfa367b499937dc","quotes":["In the ICI-treated CRC cohort, the MANTIS score was positively correlated wi... | [
"CLM:6f536da86cfa367b499937dc",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC7435056"
] | [
"SPAN:1113064a4f77249c0dc51be8"
] | [] | [] | {"qa_id":"QA:39e0e2eab615b100b0ae625e","qa_group_id":"QAG:e1c56ec9b0423c1b100e5969","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"In the ICI-treated CRC cohort, the MANTIS score was correlated wit... |
QA:3b8bd76f2aaee4cf97bfd00e | QAG:d29804012b068fe1545722f3 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Published data 35 have shown that the IL-17A level is increased in the tumor tissues of CRC patients"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Clai... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:266a97296e0b43c8c2222944","quotes":["Published data 35 have shown that the IL-17A level is increased in the tumor... | [
"CLM:266a97296e0b43c8c2222944",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC8114827"
] | [
"SPAN:9c3effeb73d80f2c0c254022"
] | [] | [] | {"qa_id":"QA:3b8bd76f2aaee4cf97bfd00e","qa_group_id":"QAG:d29804012b068fe1545722f3","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Published data 35 have shown that the IL-17A level is increased in... |
QA:3c85f5dc6a8a005645e1a578 | QAG:d4ededc4a2440070c6dc3e18 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "In mouse models, fruquintinib combined with a PD-1 inhibitor efficiently inhibited tumor growth in a syngeneic MSS-CRC model, enhancing antitumor immune response by decreasing the number of Treg cells and increasing tumor cell immunogenicity and T-cell infiltration ( 8... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ebeb33474a30b52ae2325819","quotes":["In mouse models, fruquintinib combined with a PD-1 ... | [
"CLM:ebeb33474a30b52ae2325819",
"CLM:76b5c39658e904fe9e6f7dd7",
"CLM:ec3392259a18281985fc047e",
"CLM:b0532f1ff4d34c3253c6c43b",
"CLM:073e83479839737718e14473"
] | [
"PMCID:PMC9472213",
"PMCID:PMC9720302",
"PMCID:PMC10517947"
] | [
"SPAN:90ca0f4161e3f787f5a5d152",
"SPAN:cf91727b11a68ae6f094bce2",
"SPAN:09950cd470fa50327d450eab",
"SPAN:cd4eead26c0274b6f9f66a31"
] | [
"ASC2:f5d9bd847a666648715e823f",
"ASC2:95ee1ef29d04d15bacf58f9c"
] | [
"HYP:DCH:b89570e33bc19d877138a9de"
] | {"qa_id":"QA:3c85f5dc6a8a005645e1a578","qa_group_id":"QAG:d4ededc4a2440070c6dc3e18","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"In mouse models, fruquintinib combined with a PD-1 inhibitor effic... |
QA:3daede85fb307cf1bcfedd4d | QAG:b105c8d78d67b916d8b7b99a | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "ATG16L1 emerged as a critical cytoprotective factor that inhibited IFN responses both in vivo and ex vivo; this is likely a key – but not sole – mechanism by which autophagy and ATG16L1 promote CRC fitness, as IFN signaling is known to license multiple cell death progr... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:1eed24f6722117dfaa30b52f","quotes":["ATG16L1 emerged as a critical cytoprotective factor that suppressed IFN resp... | [
"CLM:1eed24f6722117dfaa30b52f",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10517947"
] | [
"SPAN:846d96da14b81f51580d09ba"
] | [] | [] | {"qa_id":"QA:3daede85fb307cf1bcfedd4d","qa_group_id":"QAG:b105c8d78d67b916d8b7b99a","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"ATG16L1 emerged as a critical cytoprotective factor that inhibited... |
QA:3dd0c8a38606843f092b9d7f | QAG:81f4da8e77bba76fc0d190cc | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "All these chromosomal alterations have previously been identified as markers for increased risk of metastasis in colorectal cancer ( 38 )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exac... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:2753ce724be6b7c3482df04f","quotes":["Four tumors (P6648, P6335, P5915, and P5784) had imbalances in chromosome 20... | [
"CLM:2753ce724be6b7c3482df04f",
"CLM:76b5c39658e904fe9e6f7dd7"
] | [
"PMCID:PMC9811165"
] | [
"SPAN:ea2db634eaca453a15c832f6"
] | [] | [] | {"qa_id":"QA:3dd0c8a38606843f092b9d7f","qa_group_id":"QAG:81f4da8e77bba76fc0d190cc","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"All these chromosomal alterations have previously been identified ... |
QA:3ffbe48321b722c9a3f67fa7 | QAG:eb56bc3a4102d2ca9b013cb0 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Although our ORR and PFS was lower than those in the REGONIVO study, we believe that attaining such results in the real world is gratifying and represents a significant breakthrough in the treatment of MSS/pMMR CRC"? Return the original wording with paper, Claim, and E... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:7965f738128a0781e764935e","quotes":["Although our ORR and PFS were lower than those in the REGONIVO study, we bel... | [
"CLM:7965f738128a0781e764935e",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC9472213"
] | [
"SPAN:3c570ea211e7c014df378d6f"
] | [] | [] | {"qa_id":"QA:3ffbe48321b722c9a3f67fa7","qa_group_id":"QAG:eb56bc3a4102d2ca9b013cb0","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Although our ORR and PFS was lower than those in the REGONIVO stud... |
QA:4111ee1fdf7c1b0e5da76c0d | QAG:c000d0e04ff4fea4a1f6b3c7 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Patients ≥18 years of age, with previously treated, stage IV MSS CRC, and Eastern Cooperative Oncology Group 0–1, having received no prior anti-PD-1 agent were eligible"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenanc... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:932a24676f4c97971ebba1c8","quotes":["Patients ≥18 years of age, with previously treated, stage IV MSS CRC, and Ea... | [
"CLM:932a24676f4c97971ebba1c8",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10603338"
] | [
"SPAN:37f58bc775b178eebaccb5cb"
] | [] | [] | {"qa_id":"QA:4111ee1fdf7c1b0e5da76c0d","qa_group_id":"QAG:c000d0e04ff4fea4a1f6b3c7","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Patients ≥18 years of age, with previously treated, stage IV MSS C... |
QA:41e6672d53e67e45027b013c | QAG:a4546e78bac15d549fa8bd0d | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage locates the statement "Improved survival in metastatic colorectal cancer was associated with adoption of hepatic resection and improved chemotherapy"? If it is only a reference-list entry, explicitly abstain from treating it as sufficient full-text evidence.
Integrated provenance requirement... | {"answer_type":"integrated_provenance","embedded_answer_types":["limited_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":{"answer_type":"limited_evidence_retrieval","claim_id":"CLM:9446ef6ca27cd1b9670485bf","quotes":["Improved survival in metastatic colore... | [
"CLM:9446ef6ca27cd1b9670485bf",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC9648419"
] | [
"SPAN:e571fac98e1510cd2612f0b6"
] | [] | [] | {"qa_id":"QA:41e6672d53e67e45027b013c","qa_group_id":"QAG:a4546e78bac15d549fa8bd0d","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage locates the statement \"Improved survival in metastatic colorectal cancer was associated wi... |
QA:44053a1451704bdb8b6a4d7d | QAG:2310e0d42c844b295169f706 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Only CRC patients with MSS were enrolled to exclude the known genetic effects of inherited cancer syndrome"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:4bc8b759a1cb9e09e7cc9a00","quotes":["Only CRC patients with MSS were recruited to exclude the known genetic effec... | [
"CLM:4bc8b759a1cb9e09e7cc9a00",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10314951"
] | [
"SPAN:2721c0d6390dfe6855beb876"
] | [] | [] | {"qa_id":"QA:44053a1451704bdb8b6a4d7d","qa_group_id":"QAG:2310e0d42c844b295169f706","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Only CRC patients with MSS were enrolled to exclude the known gene... |
QA:453b9dc06565dcb0a16057c8 | QAG:9227f39db334687df7c01e0f | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Although Atg16l1 deletion sensitized CRC organoids to cytotoxicity promoted by Type I IFN, TLR3, and TLR4, the cell death triggered by a combination of TNF and IFNγ in Atg16l1 KO CRC organoids was more pronounced compared to other combinations (Supplementary Fig. 10c )... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:0fcea8c2ac9574fee835b80a","quotes":["Although Atg16l1 deletion sensitized CRC organoids to cytotoxicity induced b... | [
"CLM:0fcea8c2ac9574fee835b80a",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10517947"
] | [
"SPAN:fafedb95463c3061f9e4086d"
] | [] | [] | {"qa_id":"QA:453b9dc06565dcb0a16057c8","qa_group_id":"QAG:9227f39db334687df7c01e0f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Although Atg16l1 deletion sensitized CRC organoids to cytotoxicity... |
QA:459e7c4dc949e6dc3226f79a | QAG:769fff50a99d759669a5490a | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Our previous investigation indicated that the microsatellite instability-high (MSI-H) cell line might exhibit selective hyperresponsiveness to IFNγ treatment, which contributes to increased PD-L1 expression and may be a mechanism of response to anti-PD-1 therapy in col... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:b2d474f7680804de4fef4716","quotes":["Our previous investigation indicated that the micro... | [
"CLM:b2d474f7680804de4fef4716",
"CLM:2560bc1f8e2c9438c608e023"
] | [
"PMCID:PMC8114827",
"PMCID:PMC7212380"
] | [
"SPAN:242f3d146fd0461b1fda0288",
"SPAN:6dc39dfa43d2ca1c1df4235b"
] | [
"ASC2:56ef709b8fb7b2450854759b"
] | [
"HYP:DCH:f998d6a5acf98d83b8905714"
] | {"qa_id":"QA:459e7c4dc949e6dc3226f79a","qa_group_id":"QAG:769fff50a99d759669a5490a","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Our previous investigation indicated that the microsatellite insta... |
QA:4ede168ba9769588f1656705 | QAG:e946b2aa876c162c32bba791 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "21 , 22 Our previous investigation 23 indicated that an MSI cell line might exhibit selective hyperresponsiveness to IFNγ treatment, which contributes to increased PD-L1 expression and may be a mechanism of the response to anti-PD-1 therapy in colorectal cancer"? Retur... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:6da6a8e2193e538419bbd33e","quotes":["21 , 22 Our previous investigation 23 indicated that an MSI cell line might ... | [
"CLM:6da6a8e2193e538419bbd33e"
] | [
"PMCID:PMC8114827"
] | [
"SPAN:58167628ecff53b8b3c3df53"
] | [] | [] | {"qa_id":"QA:4ede168ba9769588f1656705","qa_group_id":"QAG:e946b2aa876c162c32bba791","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"21 , 22 Our previous investigation 23 indicated that an MSI cell l... |
QA:54336ee78178c7a2a5b9f10b | QAG:871cc325e16c21e98ad83bfc | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Additionally, in a Chinese clinical MSS-CRC cohort of 89 patients who received PD-1-based treatment, we found that Epigenetic_Mut was associated with favorable clinical outcomes"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:073e83479839737718e14473","quotes":["Additionally, in a Chinese clinical MSS-CRC cohort ... | [
"CLM:073e83479839737718e14473",
"CLM:76b5c39658e904fe9e6f7dd7",
"CLM:71c873fe5dde30cad48ecf08"
] | [
"PMCID:PMC9720302",
"PMCID:PMC10813565"
] | [
"SPAN:cd4eead26c0274b6f9f66a31",
"SPAN:b58976d6e10e6df790c4c1b9"
] | [
"ASC2:5ec5378df50a076c96aca581"
] | [] | {"qa_id":"QA:54336ee78178c7a2a5b9f10b","qa_group_id":"QAG:871cc325e16c21e98ad83bfc","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Additionally, in a Chinese clinical MSS-CRC cohort of 89 patients ... |
QA:54b55d2ef26db20ddf92ca50 | QAG:74da790154bc518b18be9f4a | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "ICI-treated MSI-H CRC was associated with a better prognosis than ICI-treated MSS/MSI-L CRC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and Ev... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:cc1a9a545b816c707fac65f6","quotes":["ICI-treated MSI-H CRC was associated with a better prognosis than ICI-treate... | [
"CLM:cc1a9a545b816c707fac65f6",
"CLM:76b5c39658e904fe9e6f7dd7"
] | [
"PMCID:PMC7435056"
] | [
"SPAN:1c3dc9c5ec6a9237fcd72a29"
] | [] | [] | {"qa_id":"QA:54b55d2ef26db20ddf92ca50","qa_group_id":"QAG:74da790154bc518b18be9f4a","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"ICI-treated MSI-H CRC was associated with a better prognosis than ... |
QA:554996613e74b767cba9b47d | QAG:84499c156a71d3546334f7db | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Thus, it’s implied that further investigation of regorafenib plus ICI in MSS mCRC patients should exclude those with liver metastases and novel combining strategies with ICIs were needed to overcome the innate cold tumor nature of CRC as well as the resistance promoted... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:7497a0ada45d9ebe99cf86bc","quotes":["Thus, it’s implied that further investigation of re... | [
"CLM:7497a0ada45d9ebe99cf86bc",
"CLM:76b5c39658e904fe9e6f7dd7",
"CLM:3015cde80519f486979f1ada"
] | [
"PMCID:PMC7689210",
"PMCID:PMC10186513"
] | [
"SPAN:6eedbdfbc31ce171019117cb",
"SPAN:4fbee75754e85c40a8b62900"
] | [
"ASC2:9abb47c7e5b489e5130f1f64"
] | [
"HYP:DCH:fb10c678f0b2b7962fc53f72"
] | {"qa_id":"QA:554996613e74b767cba9b47d","qa_group_id":"QAG:84499c156a71d3546334f7db","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Thus, it’s implied that further investigation of regorafenib plus ... |
QA:554ffca0ef74e06e52167fac | QAG:6dc80337d6527ff6739b2a28 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "13 Furthermore, in a study of locally advanced rectal cancer, we observed that increased serum levels of inducer of dendritic cell maturation, fms-like tyrosine kinase 3 ligand (Flt3L), were detected after administration of NACT"? Return the original wording with paper... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:53146bcb433ae97a621b3b66","quotes":["13 Furthermore, in a study of locally advanced rectal cancer, we observed th... | [
"CLM:53146bcb433ae97a621b3b66",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC7515522"
] | [
"SPAN:317eb9b7a45549959feed9d2"
] | [] | [] | {"qa_id":"QA:554ffca0ef74e06e52167fac","qa_group_id":"QAG:6dc80337d6527ff6739b2a28","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"13 Furthermore, in a study of locally advanced rectal cancer, we o... |
QA:59b1c34fff82333af28cb46e | QAG:4590053a3d8c86a63e35ff66 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Eligible patients should present histologically confirmed, MSS, metastatic (at least two evaluable lesions) CRC and have received two prior lines of chemotherapy"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:acf08a5ba0d4dd7fdad617db","quotes":["Eligible patients should present histologically confirmed, MSS, metastatic (... | [
"CLM:acf08a5ba0d4dd7fdad617db",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10586789"
] | [
"SPAN:62692822fdd94466f6e890f0"
] | [] | [] | {"qa_id":"QA:59b1c34fff82333af28cb46e","qa_group_id":"QAG:4590053a3d8c86a63e35ff66","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Eligible patients should present histologically confirmed, MSS, me... |
QA:5b30c1c773c078e5ed248f8a | QAG:e42a8a3d4c9b140493b3047d | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "In addition, azoxymethane (Sigma-Aldrich, A5486)/dextran sulfate sodium (MP Biomedicals, 9011-18-1) [azoxymethane/dextran sulfate sodium (AOM/DSS)] promoted colorectal cancer mice model were established as reported previously ( 37 )"? Return the original wording with p... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:5477854face8ffb10049a77c","quotes":["In addition, azoxymethane (Sigma-Aldrich, A5486)/dextran sulfate sodium (MP ... | [
"CLM:5477854face8ffb10049a77c",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC9414301"
] | [
"SPAN:a89bac8d2c66bfc74a10fa72"
] | [] | [] | {"qa_id":"QA:5b30c1c773c078e5ed248f8a","qa_group_id":"QAG:e42a8a3d4c9b140493b3047d","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"In addition, azoxymethane (Sigma-Aldrich, A5486)/dextran sulfate s... |
QA:5bb7cc2c7d3ab97245a303e1 | QAG:09b7e2751f04ea0343e8bd77 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "In this study, we used the CRC model promoted by MSS-type CT26 cells, which is classic type and has the characteristics of chromosomal instability"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:e4716f16a42436bdf0856b58","quotes":["In this study, we used the CRC model induced by MSS-type CT26 cells, which i... | [
"CLM:e4716f16a42436bdf0856b58",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC7212380"
] | [
"SPAN:cc316cef0c44b4c51aeafbf5"
] | [] | [] | {"qa_id":"QA:5bb7cc2c7d3ab97245a303e1","qa_group_id":"QAG:09b7e2751f04ea0343e8bd77","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"In this study, we used the CRC model promoted by MSS-type CT26 cel... |
QA:5c1b1f7c0c2c5a54d735e8f0 | QAG:d104954ad1c25f86ce62bbcc | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage locates the statement "Circulating tumor DNA analysis detects minimal residual disease and predicted recurrence in patients with stage II colon cancer"? If it is only a reference-list entry, explicitly abstain from treating it as sufficient full-text evidence.
Integrated provenance requireme... | {"answer_type":"integrated_provenance","embedded_answer_types":["limited_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":{"answer_type":"limited_evidence_retrieval","claim_id":"CLM:119163482eadac8c9e9386f8","quotes":["Circulating tumor DNA analysis detects... | [
"CLM:119163482eadac8c9e9386f8",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC9648419"
] | [
"SPAN:bc2bf1c278edfe091649ea43"
] | [] | [] | {"qa_id":"QA:5c1b1f7c0c2c5a54d735e8f0","qa_group_id":"QAG:d104954ad1c25f86ce62bbcc","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage locates the statement \"Circulating tumor DNA analysis detects minimal residual disease and... |
QA:5e7ff4f1e188ab01d9709506 | QAG:d9350d67297fa1c5249bd07c | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "26–29 To examine the influence of CCRT on the levels of type I IFN signatures in CRC patients, we first compared 20 CRC patients who received CCRT from the GSE93375 dataset by gene set enrichment analysis (GSEA), and the results indicated that the type I IFN signatures... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:29a278445016a2810f10a0b3","quotes":["26–29 To examine the influence of CCRT on the levels of type I IFN signature... | [
"CLM:29a278445016a2810f10a0b3",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10813565"
] | [
"SPAN:bb72120b098b5ff2ba333191"
] | [] | [] | {"qa_id":"QA:5e7ff4f1e188ab01d9709506","qa_group_id":"QAG:d9350d67297fa1c5249bd07c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"26–29 To examine the influence of CCRT on the levels of type I IFN... |
QA:5f98d0fb09e374c562e3ca59 | QAG:2d2b0914bbfba6d69a6b6e20 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Despite the success of checkpoint blockade in solid tumors, non-MSI CRC has consistently failed to meet an appreciable response to immunotherapy"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return t... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:829870f749d09a9263579d03","quotes":["Despite the success of checkpoint blockade in solid tumors, non-MSI CRC has ... | [
"CLM:829870f749d09a9263579d03",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10517947"
] | [
"SPAN:6944844754e5892ecce37dda"
] | [] | [] | {"qa_id":"QA:5f98d0fb09e374c562e3ca59","qa_group_id":"QAG:2d2b0914bbfba6d69a6b6e20","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Despite the success of checkpoint blockade in solid tumors, non-MS... |
QA:5fe3e499a66e75283dd15311 | QAG:e03f7a0265772177b4b9a145 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Direct treatment with IFNβ on colorectal cancer cells also remarkably increased PD-L1 expression ( figure 1(f ))"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:943794caec0ad542b611b343","quotes":["Direct treatment with IFNβ on colorectal cancer cells also remarkably enhanc... | [
"CLM:943794caec0ad542b611b343",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10813565"
] | [
"SPAN:292060fab880f460bcb59f08"
] | [] | [] | {"qa_id":"QA:5fe3e499a66e75283dd15311","qa_group_id":"QAG:e03f7a0265772177b4b9a145","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Direct treatment with IFNβ on colorectal cancer cells also remarka... |
QA:601b2dedbeb4b27aa649645c | QAG:9784981db8db88da78ec68d3 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Moreover, we established a risk score, which was associated with PD-L1 expression and could reflect both the level of tumor-infiltrating immune cells and the prognosis of MSS-EO-CRC patients"? Return the original wording with paper, Claim, and Evidence Span references.... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:badee85825445d9a0d53c82c","quotes":["Moreover, we established a risk score, which was po... | [
"CLM:badee85825445d9a0d53c82c",
"CLM:64822c34f03e6ab9a02ee6f5",
"CLM:6b941dc0e10ae8a3c94344d2"
] | [
"PMCID:PMC10314951",
"PMCID:PMC9422817"
] | [
"SPAN:17a3b17363d153d1b8371f98",
"SPAN:94b21760c2bbf6cb4478e4ba"
] | [
"ASC2:b520e87ff1deb6962ea11c18"
] | [
"HYP:DCH:bfa6cb189d878ca877171096"
] | {"qa_id":"QA:601b2dedbeb4b27aa649645c","qa_group_id":"QAG:9784981db8db88da78ec68d3","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Moreover, we established a risk score, which was associated with P... |
QA:60b873aca4e88b90835c0062 | QAG:d84c0730c03b8e4b3402ce20 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "On this basis, we hypothesized that prevention of TGFβ promoted immune exclusion along with immune checkpoint blockade may eliminate colorectal cancer micrometastases still present after resection of all evident disease"? Return the original wording with paper, Claim, ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:4379d2a66a7917847c4136c5","quotes":["On this basis, we hypothesized that prevention of TGFβ-induced immune exclus... | [
"CLM:4379d2a66a7917847c4136c5",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC9648419"
] | [
"SPAN:f9b05c468c7d95f170e857b0"
] | [] | [] | {"qa_id":"QA:60b873aca4e88b90835c0062","qa_group_id":"QAG:d84c0730c03b8e4b3402ce20","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"On this basis, we hypothesized that prevention of TGFβ promoted im... |
QA:636407419dadb32e189f5f4b | QAG:f0b0ef27eb9ec67e9cb06f41 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Our current study indicates that high ATG16L1 expression predicted poor immunotherapy response in CRC, which can be explained mechanistically by ATG16L1-mediated inhibition of IFN signaling and a consequent suppression of cellular immunity"? Return the original wording... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:91a7beb6a9dd7c7e1b15eb82","quotes":["Our current study indicates that high ATG16L1 expression predicts poor immun... | [
"CLM:91a7beb6a9dd7c7e1b15eb82",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10517947"
] | [
"SPAN:da0e6bc955390761583a3ae2"
] | [] | [] | {"qa_id":"QA:636407419dadb32e189f5f4b","qa_group_id":"QAG:f0b0ef27eb9ec67e9cb06f41","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Our current study indicates that high ATG16L1 expression predicted... |
QA:66350342543eadf480a1162a | QAG:24a6fcd2aac845e8c030478e | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "In our experiment, IFNγ exposure in vitro induced increased PD-L1 mRNA expression in line with the enhanced protein expression, which demonstrated that the upregulated PD-L1 molecules on CRC cell lines may be the result of IFNγ/PD-L1 signaling activation and new mRNA t... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9d46b42f3c0876791a6a67e3","quotes":["In our experiment, IFNγ exposure in vitro induced increased PD-L1 mRNA expre... | [
"CLM:9d46b42f3c0876791a6a67e3"
] | [
"PMCID:PMC8114827"
] | [
"SPAN:e1914d6746d8db4e64dfdd52"
] | [] | [] | {"qa_id":"QA:66350342543eadf480a1162a","qa_group_id":"QAG:24a6fcd2aac845e8c030478e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"In our experiment, IFNγ exposure in vitro induced increased PD-L1 ... |
QA:6668fed5bb3621cf79e34573 | QAG:aa8c044ac053c5b4f3d40fca | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "While prior studies failed to meet a benefit from PDCD1 (PD-1) targeting in CD274-positive MSS stage IV CRC, such studies implemented a low cut-off for CD274 positivity and did not include lymphocytic infiltration as an inclusion factor (53)"? Return the original wordi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:48dd0a54bfab807ee71d7163","quotes":["While prior studies failed to show a benefit from\n... | [
"CLM:48dd0a54bfab807ee71d7163",
"CLM:64822c34f03e6ab9a02ee6f5",
"CLM:187792abec08d7cee4862b6a"
] | [
"PMCID:PMC6763253",
"PMCID:PMC9472213"
] | [
"SPAN:4938d19eebfc3148e852f4d5",
"SPAN:c469af1f48069fbc99c3bd50"
] | [
"ASC2:aa0c1cc43b8a0bd09f12e9c1"
] | [
"HYP:DCH:f7386e0c43b03063ff619685"
] | {"qa_id":"QA:6668fed5bb3621cf79e34573","qa_group_id":"QAG:aa8c044ac053c5b4f3d40fca","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"While prior studies failed to meet a benefit from PDCD1 (PD-1) tar... |
QA:6741e1f4ce890d1c15120595 | QAG:49cd32e83d2de5ef57dac35f | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "CRC patients across clinical stages with available information of both OS and RFS outcomes were included in our analyses"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting pass... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:aa1df10e0c399b25dac5d501","quotes":["CRC patients across\nclinical stages with available information of both OS a... | [
"CLM:aa1df10e0c399b25dac5d501",
"CLM:76b5c39658e904fe9e6f7dd7"
] | [
"PMCID:PMC6763253"
] | [
"SPAN:0142c6b2dd27665d858fd717"
] | [] | [] | {"qa_id":"QA:6741e1f4ce890d1c15120595","qa_group_id":"QAG:49cd32e83d2de5ef57dac35f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"CRC patients across clinical stages with available information of ... |
QA:69cf41ca3aa54e7480c4f313 | QAG:2728bd7d9d74d0a68f3b9fff | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Finally, we validated the predictive power of epigenetic-related gene mutations in the HMUCH cohort of 89 MSS CRC patients who received immunotherapy and discovered that patients with epigenetic mutations were more likely to benefit from ICI-based combination therapy a... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:fe8fcfebf99de25acf3dcae1","quotes":["Finally, we validated the predictive power of epigenetic-related gene mutati... | [
"CLM:fe8fcfebf99de25acf3dcae1",
"CLM:76b5c39658e904fe9e6f7dd7"
] | [
"PMCID:PMC9720302"
] | [
"SPAN:da10a1693242ec44d7d5c536"
] | [] | [] | {"qa_id":"QA:69cf41ca3aa54e7480c4f313","qa_group_id":"QAG:2728bd7d9d74d0a68f3b9fff","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Finally, we validated the predictive power of epigenetic-related g... |
QA:6cb49f58afb5c6ff3185e731 | QAG:791cf5bdb6cb81713384bc88 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Measurements of number of metastases (A) and tumor volume (B) for patients with liver-limited metastatic colorectal cancer who received standard-of-care (SOC) observation or BA (trial cohort)"? Return the original wording with paper, Claim, and Evidence Span references... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:bdec48bf63f290f52c2ea924","quotes":["Measurements of number of metastases (A) and tumor volume (B) for patients w... | [
"CLM:bdec48bf63f290f52c2ea924",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC9648419"
] | [
"SPAN:402d7036a43850dcec315826"
] | [] | [] | {"qa_id":"QA:6cb49f58afb5c6ff3185e731","qa_group_id":"QAG:791cf5bdb6cb81713384bc88","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Measurements of number of metastases (A) and tumor volume (B) for ... |
QA:6e931c6f93e3fd236ce32c5d | QAG:567989c483870971d34f4f39 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Targeting C-6-S combined with anti–PD-1 strategy in AOM/DSS promoted colorectal cancer model"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and E... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:a8383ace6b9a321690b438c4","quotes":["Data are presented as mean ± SD. ****, P < 0.0001; ***, P < 0.001; **, P < 0... | [
"CLM:a8383ace6b9a321690b438c4",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC9414301"
] | [
"SPAN:479f3397852dedfb2a85e8bb"
] | [] | [] | {"qa_id":"QA:6e931c6f93e3fd236ce32c5d","qa_group_id":"QAG:567989c483870971d34f4f39","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Targeting C-6-S combined with anti–PD-1 strategy in AOM/DSS promot... |
QA:6f86d95368be0713c80f9fd6 | QAG:d0595abe838d156c6dcf1e5c | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Figure 6 Treatment promoted changes in peripheral blood immune cells of patients with metastatic colorectal cancer"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage wi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:7aca8be2fdc44672407c426c","quotes":["Figure 6 Treatment-induced changes in peripheral blood immune cells of patie... | [
"CLM:7aca8be2fdc44672407c426c",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10603338"
] | [
"SPAN:7faa6945018582aac0020ecf"
] | [] | [] | {"qa_id":"QA:6f86d95368be0713c80f9fd6","qa_group_id":"QAG:d0595abe838d156c6dcf1e5c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Figure 6 Treatment promoted changes in peripheral blood immune cel... |
QA:7022abcc083574e6b3c05f6c | QAG:630d3f648bfbe02ed1e21981 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "MSI-H/dMMR CRC stimulates tumor antigen synthesis by increasing TMB, resulting in increased T-cell infiltration in the TME and responding well to ICIs ( 11 , 12 )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:265016ea0a327dbdbc15e894","quotes":["MSI-H/dMMR CRC stimulates tumor antigen synthesis b... | [
"CLM:265016ea0a327dbdbc15e894",
"CLM:76b5c39658e904fe9e6f7dd7",
"CLM:7c490a6b1190b25486e6a054"
] | [
"PMCID:PMC9472213",
"PMCID:PMC7435056"
] | [
"SPAN:e159d7aad921de3b328ca43b",
"SPAN:a1a08a634855e47d6cb44fef"
] | [
"ASC2:0fc89e734256ab1306f1f803"
] | [
"HYP:DCH:d91f41965535b9f147add304"
] | {"qa_id":"QA:7022abcc083574e6b3c05f6c","qa_group_id":"QAG:630d3f648bfbe02ed1e21981","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"MSI-H/dMMR CRC stimulates tumor antigen synthesis by increasing TM... |
QA:7092e753324443481686589b | QAG:e3c8cfa791ff0273cc58ed48 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "The expression of immune checkpoint genes, such as LAG3, CTLA4, CD274, PDCD1, TIGIT, IDO1, and PDCD1LG2, in MSI-H CRC was higher than that in MSS/MSI-L CRC ( Figure 3F ; all P ≤ 0.05), while MSI-H CRC exhibited lower expression of VEGF"? Return the original wording wit... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:659ef7d18e4ea5a3c97edb3b","quotes":["The expression of immune checkpoint genes, such as ... | [
"CLM:659ef7d18e4ea5a3c97edb3b",
"CLM:64822c34f03e6ab9a02ee6f5",
"CLM:48dd0a54bfab807ee71d7163"
] | [
"PMCID:PMC7435056",
"PMCID:PMC6763253"
] | [
"SPAN:4b0de99c0e53ce4bbb5ca10f",
"SPAN:4938d19eebfc3148e852f4d5"
] | [
"ASC2:2e93484a1b2e00bd39c9d099"
] | [
"HYP:DCH:9de996ef4bc666260e5e6f74"
] | {"qa_id":"QA:7092e753324443481686589b","qa_group_id":"QAG:e3c8cfa791ff0273cc58ed48","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"The expression of immune checkpoint genes, such as LAG3, CTLA4, CD... |
QA:70deffb8dfc97e958c839c4f | QAG:5ccfbc80accd6801fcb07966 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "NK cells was associated with the prolonged survival of CRC patients ( 46 )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and Evidence Span refer... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c2b7eea56e03c6a8f05a9ebd","quotes":["NK cells are associated with the prolonged survival of CRC patients ( 46 )."... | [
"CLM:c2b7eea56e03c6a8f05a9ebd",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC7435056"
] | [
"SPAN:2ab9bfe5965f5fdd39112a96"
] | [] | [] | {"qa_id":"QA:70deffb8dfc97e958c839c4f","qa_group_id":"QAG:5ccfbc80accd6801fcb07966","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"NK cells was associated with the prolonged survival of CRC patient... |
QA:7289648526f0d26a45cb7ccf | QAG:568e3f62f2222e6163c36d08 | provenance_qa | paper_evidence_availability | provenance_qa | G008 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC7746197? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC7746197","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC7746197"
] | [] | [] | [] | {"qa_id":"QA:7289648526f0d26a45cb7ccf","qa_group_id":"QAG:568e3f62f2222e6163c36d08","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G008","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC7746197... |
QA:7302f518a5bb272fe318a2fd | QAG:8034e94be8742e2b58069984 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "We identified a risk population showing high CD8A coupled with intense CD274 gene expression among CRC patients, which was associated with poor prognosis and absent in melanoma"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated p... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:6a69b01a6cc40d1bd7ad1af1","quotes":["We identified a\nrisk population showing high CD8A coupled with intense CD27... | [
"CLM:6a69b01a6cc40d1bd7ad1af1",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC6763253"
] | [
"SPAN:da50210e1c8f38772b3970b6"
] | [] | [] | {"qa_id":"QA:7302f518a5bb272fe318a2fd","qa_group_id":"QAG:8034e94be8742e2b58069984","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"We identified a risk population showing high CD8A coupled with int... |
QA:73848b363bd7083d80f35609 | QAG:bf5759f7f50ce1d43519914a | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Therefore, the expression promoted by exogenous cytokines including IFNγ, was the main source of expression of PD-L1 on CRC cells"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact suppor... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:1ea65571f571ea27c871c8be","quotes":["Therefore, the expression induced by exogenous cytokines including IFNγ, was... | [
"CLM:1ea65571f571ea27c871c8be",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC8114827"
] | [
"SPAN:ae871f163b6977be6f11fd6b"
] | [] | [] | {"qa_id":"QA:73848b363bd7083d80f35609","qa_group_id":"QAG:bf5759f7f50ce1d43519914a","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Therefore, the expression promoted by exogenous cytokines includin... |
QA:73bfff78aa61c04f77db202c | QAG:fd7dcaad99939117bb0f8ce8 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Additionally, in a Chinese clinical MSS-CRC cohort of 89 patients who received PD-1-based treatment, we found that Epigenetic_Mut was associated with favorable clinical outcomes"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f344460c593f2a19fe644725","quotes":["Additionally, in a Chinese clinical MSS-CRC cohort of 89 patients who receiv... | [
"CLM:f344460c593f2a19fe644725",
"CLM:76b5c39658e904fe9e6f7dd7"
] | [
"PMCID:PMC9720302"
] | [
"SPAN:cd4eead26c0274b6f9f66a31"
] | [] | [] | {"qa_id":"QA:73bfff78aa61c04f77db202c","qa_group_id":"QAG:fd7dcaad99939117bb0f8ce8","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Additionally, in a Chinese clinical MSS-CRC cohort of 89 patients ... |
QA:75bf80c90c806164568ebf8e | QAG:9764787544ddfe5d1c8bb19a | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Twelve hours later, the expression of STAT1 in both types of CRC cell lines increased ( Figure 2D )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9e42939b3488460d68bf4455","quotes":["Twelve hours later, the expression of STAT1 in both types of CRC cell lines ... | [
"CLM:9e42939b3488460d68bf4455",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC8114827"
] | [
"SPAN:5addd2ef8f559710a18bacec"
] | [] | [] | {"qa_id":"QA:75bf80c90c806164568ebf8e","qa_group_id":"QAG:9764787544ddfe5d1c8bb19a","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Twelve hours later, the expression of STAT1 in both types of CRC c... |
QA:781c7ba99de939b5d00deb9b | QAG:cd8599696a0d34cd1fb04e47 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Two targeting loci (cg15837913 and cg19724470) within the PD-L1 promoter regions was associated with survival outcome in several malignancies, such as prostate cancer, colorectal cancer, and lymphoma"? Return the original wording with paper, Claim, and Evidence Span re... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:522cedb2a22a967583f1c7f2","quotes":["Two targeting loci (cg15837913 and cg19724470) within the PD-L1 promoter reg... | [
"CLM:522cedb2a22a967583f1c7f2",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10813565"
] | [
"SPAN:5f993633babdbcee00b3aaac"
] | [] | [] | {"qa_id":"QA:781c7ba99de939b5d00deb9b","qa_group_id":"QAG:cd8599696a0d34cd1fb04e47","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Two targeting loci (cg15837913 and cg19724470) within the PD-L1 pr... |
QA:7bba46ff64cdcd7edafd2c7d | QAG:23ca149b0621cb5982724121 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Based on the somatic mutation data of MSS-EO-CRC patients from TCGA, we predicted the candidate driving genes using the MutSigCV algorithm with a p -value less than 0.001. As displayed in Fig. 7a , five genes have been identified as the significantly mutated genes (SMG... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:24079bb448f4d5814d7e4da2","quotes":["Based on the somatic mutation data of MSS-EO-CRC patients from TCGA, we pred... | [
"CLM:24079bb448f4d5814d7e4da2",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10314951"
] | [
"SPAN:143a2dcbf5d0a2354a2f9597"
] | [] | [] | {"qa_id":"QA:7bba46ff64cdcd7edafd2c7d","qa_group_id":"QAG:23ca149b0621cb5982724121","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Based on the somatic mutation data of MSS-EO-CRC patients from TCG... |
QA:7ca422265aa7525754c5344b | QAG:a0d1cfb4b833c3bb6dc25dd1 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "DNMTi increased the therapeutic efficacy of concurrent chemoradiotherapy and anti-PD-L1 immunotherapy in CRC in vivo. (a) Resected tumors from representative mice were analyzed by RNA-seq (n = 2)"? Return the original wording with paper, Claim, and Evidence Span refere... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:05a636a9da461c0abfd507de","quotes":["Figure 6. DNMTi enhanced the therapeutic efficacy of concurrent chemoradioth... | [
"CLM:05a636a9da461c0abfd507de",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10813565"
] | [
"SPAN:a0f279abff9a24a81a4bc40d"
] | [] | [] | {"qa_id":"QA:7ca422265aa7525754c5344b","qa_group_id":"QAG:a0d1cfb4b833c3bb6dc25dd1","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"DNMTi increased the therapeutic efficacy of concurrent chemoradiot... |
QA:7ce7ab6dcb7b550fe2cb4b61 | QAG:0b64234efc14388384dc66c5 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Further analyses revealed that caspase-8 knockout RIPK3-positive colorectal cancer models were sensitive to tolinapant promoted necroptosis, an effect that could be exploited in caspase-8-proficient models using the clinically relevant caspase inhibitor emricasan"? Ret... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f3c9e7799284066cf19b3bf2","quotes":["Further analyses revealed that caspase-8 knockout RIPK3-positive colorectal ... | [
"CLM:f3c9e7799284066cf19b3bf2",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC7611622"
] | [
"SPAN:331ae1b12c33affc168cd4d9"
] | [] | [] | {"qa_id":"QA:7ce7ab6dcb7b550fe2cb4b61","qa_group_id":"QAG:0b64234efc14388384dc66c5","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Further analyses revealed that caspase-8 knockout RIPK3-positive c... |
QA:7d64639ae3827ab8556703db | QAG:f6bb3b2a39a8f8c4ba9e6fab | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "On this basis, we hypothesized that prevention of TGFβ promoted immune exclusion along with immune checkpoint blockade may eliminate colorectal cancer micrometastases still present after resection of all evident disease"? Return the original wording with paper, Claim, ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:20cf718b4df5ab9dd6c13e6a","quotes":["On this basis, we hypothesized that prevention of TGFβ-induced immune exclus... | [
"CLM:20cf718b4df5ab9dd6c13e6a",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC9648419"
] | [
"SPAN:df67954e6c338991772d2db1"
] | [] | [] | {"qa_id":"QA:7d64639ae3827ab8556703db","qa_group_id":"QAG:f6bb3b2a39a8f8c4ba9e6fab","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"On this basis, we hypothesized that prevention of TGFβ promoted im... |
QA:7e0da14fab16b5ee4960a482 | QAG:c7f04032305de71fdf7670ba | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Collectively, these results show that absence of Atg16l1 sensitizes CRC organoids to TNF + IFNγ promoted necroptosis and apoptosis"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact suppo... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:6b9890b215a9d202dc686234","quotes":["Collectively, these results show that absence of Atg16l1 sensitizes CRC orga... | [
"CLM:6b9890b215a9d202dc686234",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10517947"
] | [
"SPAN:2b545ee66870645f9bc3348b"
] | [] | [] | {"qa_id":"QA:7e0da14fab16b5ee4960a482","qa_group_id":"QAG:c7f04032305de71fdf7670ba","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Collectively, these results show that absence of Atg16l1 sensitize... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.